welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
PTC Therapeutics, Inc. today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year’s funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.
“We were overwhelmed to receive so many outstanding applications in the first year of PRIORITY and to see such a breadth of ideas to improve the screening and diagnosis of Duchenne,” said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics, Inc. “We are thrilled that the PRIORITY program will help bring these research projects to fruition and ultimately help patients receive the best care as early as possible.”
rareRelated
-
PDE Inhibitors in DMD Study (Acute Dosing Study)PDE5A inhibition, which boosts NO-cGMP s...
-
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
-
New lab technology could reveal treatments for muscle-wasting diseaseResearchers from Queen Mary University o...
-
Bespoke Is Often Better: How Scientists Are Customizing Gene TherapyWhen it comes to products from suits to ...
-
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular DystrophyThis study is being performed as a post-...
-
New Drug for Duchenne Muscular Dystrophy Clears Phase 1 Clinical Trial Testing in BoysPatients with Duchenne muscular dystroph...
-
The Muscular Dystrophy AssociationThe Muscular Dystrophy Association is co...
